Recruiting NA INTERVENTIONAL 2-arm NCT05653518

Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes (WBH002)

Using Closed-Loop Artificial Pancreas Technology to Reduce Glycemic Variability and Subsequently Improve Cardiovascular Health in Type 1 Diabetes

Sponsor: University of Virginia

Conditions Type 1 Diabetes

Interventions Sensor augmented pump (SAP) therapy Tandem t:slim X2 with Control-IQ Technology

Updated 11 times since 2023 Last updated: Feb 23, 2026 Started: Sep 9, 2023 Primary completion: Mar 30, 2027 Completion: Mar 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Type 1 Diabetes and is currently actively recruiting participants. University of Virginia leads this study, which shows 11 recorded versions since 2023 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

11 versions recorded

Feb 2026 — Present [monthly]

Recruiting NA
May 2025 — Feb 2026 [monthly]

Recruiting NA
Sep 2024 — May 2025 [monthly]

Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Recruiting NA
Jun 2024 — Jul 2024 [monthly]

Recruiting NA

▶ Show 6 earlier versions

Mar 2024 — Jun 2024 [monthly]

Recruiting NA
Oct 2023 — Mar 2024 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
Sep 2023 — Oct 2023 [monthly]

Not Yet Recruiting NA
Aug 2023 — Sep 2023 [monthly]

Not Yet Recruiting NA
Mar 2023 — Aug 2023 [monthly]

Not Yet Recruiting NA
Jan 2023 — Mar 2023 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Virginia

Data source: University of Virginia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Charlottesville, United States